Short Interest Analysis: MLYS
Mineralys Therapeutics (MLYS) is currently reporting 9.2 million shares held short. The days-to-cover ratio stands at 6.4, which is a notable figure for a biotech-related equity. The borrow fee is currently 0.4%, indicating that despite the significant short interest, the stock remains easy to borrow for market participants.
Market Context
With a cash runway of 8.3 months and a 78% increase in shares outstanding over the last two years, the company's capital structure is a key focus for investors. The current short interest reflects a cautious outlook from the market, though the low borrow fee suggests that the cost of maintaining these positions is minimal.
Key Takeaways
- 9.2 million shares are held short.
- Days-to-cover ratio is 6.4.
- Borrow fee is low at 0.4%.
The Bottom Line
MLYS shows a consistent short-side presence, but the lack of borrow fee pressure suggests that the market is not currently anticipating a near-term squeeze.
Signal data sourced from CurvedTrading. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.